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ABSTRACT 
Objectives: To examine the effect of lymphadenectomy on survival in patients with squamous cell vulvar carcinoma.
Material and methods: Patients with squamous cell vulvar cancer who underwent surgery were retrospectively analyzed. 
All procedures were performed according to current recommendations/standard of treatment. The clinical and pathologi-
cal features were examined. Sixty-eight patients were studied. The mean age was 64.7 ± 10.9 years. Twenty-three (33.8%) 
patients had nodal metastasis. Most patients (60.3%) were in stage IB.  Adjuvant radiotherapy and chemo-radiotherapy were 
administered to 33.8% and 25% of the patients, respectively. The median follow-up time was 28.5 (4–183) months. Recur-
rence occurred in 18 (26.5%) cases.
Results: There was no significant difference between node-positive and node-negative patients in terms of age, number of 
dissected lymph nodes and recurrence. Tumor diameter was significantly higher in the metastatic group. Age and surgical 
margin positivity were independent prognostic factors for overall survival (OS). Surgical margin positivity and lymph node 
metastasis had no effect on disease-free survival (DFS).
Conclusions: Our results showed that age and surgical margin positivity were independent prognostic factors for OS. 
Although surgical margin positivity increased the risk of recurrence in univariate analysis, it was not a significant factor 
affecting DFS. OS was significantly lower in patients with lymph node metastasis.
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INTRODUCTION
The incidence of vulvar cancer was reported to be 1.1 per 
100.000 women in Poland [1]. Surgery is the mainstay treat-
ment for early stage vulvar cancer [2–4].  However, definitive 
radiotherapy (RT) and chemo-radiotherapy (CRT) should be 
selected in patients with distant metastasis, locally advanced 
disease and older patients with medical comorbidities that 
are not fit for surgery [4]. Adjuvant treatment was found 
to increase disease-free survival (DFS) and overall survival 
(OS) in node-positive patients, but the information on the 
role of RT and CRT in node-negative patients is lacking [5].
The prognostic factors for vulvar cancer have been in-
vestigated in several studies [6–8]. Tumor invasion deeper 
than 2 mm was found to be a risk factor for local recur-
rence [9]. Lymphovascular space involvement (LVSI) was 
also an independent risk factor for local recurrence [10]. 
Additionally, HPV-positive patients had less local recurrence 
than HPV-negative patients [11]. Conflicting data is present 
on the role of lymph node metastasis on recurrence in the 
literature [9, 12, 13]. Some authors reported that lymph node 
positivity was related with increased disease recurrence [12]. 
On the other hand, several studies have reported that lymph 
node metastasis had no effect on recurrence [9, 13]. Surgi-
cal margin distance was also studied in several reports, and 
there is conflicting data on the role of the margin distance 
on recurrence [14, 15]. There are also contradictory data on 
the effect of tumor size and grade on survival [6, 14].
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Objectives
The aim of this study was to investigate the effect of 
lymph node metastasis on survival in vulvar cancer patients.
MATERIAL AND METHODS 
Patients with vulvar cancer who were treated between 
January 1995 and November 2018 were retrospectively 
analyzed.  A total of 98 patients were encountered dur-
ing the study period. Those with non-squamous histology 
(n = 13) and those treated with definitive RT or CRT (n = 17) 
were excluded. The data of the patients were obtained from 
patients’ files and the hospital database. The collected data 
were tumor size, distance from midline (clitoris), association 
with urethra, anus and vagina, the status of inguinofemoral 
lymph nodes, Human Papilloma Virus (HPV) status, exami-
nation results of other parts of the lower genital tract, pre-
operative radiologic evaluation including posteroanterior 
X-ray, computed tomography, magnetic resonance imaging 
and positron emission tomography. All gynecologic exami-
nations were performed by gynecologic oncologists, and all 
pathologic slides were evaluated by experienced gynecopa-
tologists. The preoperative findings of the patients were dis-
cussed in a multidisciplinary tumor board. The decision on 
optimal treatment was made according to age, performance 
status, diameter of tumor, status of lymph node metastasis 
and stage of the disease. The criteria for inguinofemoral lym-
phadenectomy (superficial and deep) was tumor diameter 
larger than 2 cm. Sentinel lymphadenectomy was utilized to 
decrease the morbidity of full lymphadenectomy in unifocal 
tumors that were smaller than 4 cm and cases with clini-
cally negative lymph nodes. Positive surgical margin was 
specified as continuity of the tumor at the surgical margin 
or tumor in the surgical margin below 8 mm. Surgical stag-
ing was performed according to International Federation 
of Gynecology and Obstetrics (FIGO) 2009 [16]. The criteria 
recommended in National Comprehensive Cancer Network 
(NCCN) 2017 vulvar cancer guidelines were used for adju-
vant treatment. [4]. Performance status and risk factors for 
recurrence were the factors affecting adjuvant treatment 
decision. Adjuvant RT was administered 6 weeks after sur-
gery. Adjuvant CRT regime was addition of 40 mg/m2 cispl-
atin or 5-Fluorouracil to RT. The follow-up period was every 
3 months for the first 2 years, every 6 months for the next 
3 years and annual controls thereafter. Each follow-up visit 
included vulvovaginal and pelvic examination and imaging 
procedures in the suspicion of recurrence.
A total of 68 patients with vulvar squamous cell car-
cinoma (SCC) were enrolled in the study. The clinical and 
pathological features of the patients are shown in Table 1. 
The mean age was 64.7 ± 10.9 years. The most common 
(37.6%) localization of the tumor was the right side of the 
vulva and ≤ 2 cm from the midline. The median tumor di-
ameter was 2.8 cm (0.1–8.5). Most tumors were smaller 
than 4 cm (88.2%).  Tumor grade 1, 2 and 3 were found to 
be 50.0%, 47.1% and 2.9%, respectively. LVSI was detected in 
13.2% of the cases. Information on HPV status was available 
only in 25 patients. Surgical margin positivity was found to 
be in 11.8% of the patients. Sentinel lymphadenectomy 
was performed in 8.8% of the patients, and all nodes were 
non-metastatic. Twenty-three (33.8%) patients had nodal 
Table 1. Clinical data of patients
n = 68 (%)
Age [years], mean ± SD 64.7 ±  10.9
Treatment 
Only surgery
Surgery + RT/RCT
28 (41.2)
40 (58.8)
Type of surgery
Radical vulvectomy
Simple vulvectomy
Wide local Excision
55 (80.9)
9 (13.2)
4 (5.9)
IFN lymhadenectomy
Ipsilateral
Bilateral
Sentinel
7 (10.3)
55 (80.9)
6 (8.8)
Dissected lymph node count, median [range] 11 [8–32]
Tumor diameter, median [range], cm
≤ 4 cm
> 4 cm 
2.8 [0.1–8.5]
60 (88.2) 
8 (11.8)
Surgical margin
Positive
Negative
8 (11.8)
60 (88.2)
Grade
1
2
3
34 (50.0)
32 (47.1)
2 (2.9)
LVSI 9 (13.2)
Stage
I
IA
IB
II
III
IIIA
IIIB
IIIC 
IV
IVA
IVB 
45 (66.2)
4 (5.9)
41 (60.3)
0 (0)
21 (30.9)
11 (16.2)
3 (4.4)
7 (10.3)
2 (3.0)
1 (1.5)
1 (1.5)
Lymph node metastasis 23 (33.8)
Recurrence
Local
Groin recurrence
Distant Metastasis
18 (26.5)
11 (61.1)
4 (22.2)
3 (16.7)
Adjuvant treatment
None
RT
CRT
28 (41.2)
23 (33.8)
17 (25)
SD — standard deviation; RT — Radiotherapy; CRT — Chemoradiotherapy; 
IFN — Inguinofemoral; LVSI — lymphovascular space invasion
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metastasis. The most frequent (60.3%) stage was Stage IB. 
While 28 (41.2%) patients undergoing primary surgery did 
not receive adjuvant therapy, 23 (33.8%) were treated with 
adjuvant RT and 17 (25%) with CRT. The median follow-up 
time was 28.5 (4–183) months. Recurrence occurred in 
18 cases (26.5%). The most common (61.1%) recurrence 
site was local recurrence in the surgical field. Three (16.7%) 
patients had distant recurrences, and the remaining (22.2%) 
had recurrences in inguinofemoral lymph nodes. Secondary 
surgery was performed in 33.3% of all recurrent patients.
The institutional ethics committee approval was re-
ceived for the study. SPSS software Ver.22 (SPSS Inc. Chicago, 
USA) was used for statistical analysis. Independent sample 
t-test, Mann Whitney U-test and Chi-squared test were used 
to determine the differences between the groups. Log-rank 
test was used to compare the factors affecting survival. 
Kaplan-Meier method was performed to estimate the OS 
and DFS. Cox univariate and multivariate regression analysis 
were performed to detect the prognostic factors for survival. 
p < 0.05 was considered as statistically significant.
RESULTS 
The 5-year OS rate was 62.2%, and the 5-year DFS rate 
was 59.6%. The mean OS of the group with lymph node 
metastasis (23 patients) was 67.0 months, while the mean OS 
of the non-metastatic group (45 patients) was 115.4 months 
(p = 0.028). OS was significantly higher in patients without 
lymph node metastasis. OS and DFS analyses for lymph 
node status are shown in Figures 1 and 2. The mean OS 
for the surgical margin-negative (60 patients) and positive 
(8 patients) patients were 107.9 months and 17.2 months, 
respectively (p = 0.003).  
The clinicopathological features of the patients accord-
ing to lymph node status are shown in Table 2. When those 
with and without lymph node metastasis were compared, 
there was no significant difference in terms of age, tumor 
localization, grade, number of dissected lymph nodes and 
recurrence. Tumor diameter was higher in the metastatic 
group (p = 0.01). LVSI and adjuvant treatment were more 
common in node-positive patients (p = 0.05, p < 0.01, re-
spectively). 
OS and DFS analyses of the patients are shown in Table 3. 
Age, surgical margin and lymph node metastasis were de-
tected as significant prognostic factors for OS in univariate 
analysis (p = 0.011, p = 0.001, p = 0.039, respectively). In 
multivariate analysis, age and surgical margin positivity were 
important independent prognostic factors for OS [OR 1.07, 
95% CI (1.01–1.12) p = 0.015; OR 4.76, 95 % CI (1.46–15.53) 
p = 0.010, respectively]. Tumor diameter, lymph node me-
tastasis and adjuvant treatment had no effect on OS in 
the multivariate analysis. Surgical margin positivity was 
a significant prognostic factor for DFS in univariate analysis 
[OR 2.81, 95% CI (0.59–13.2) p = 0.020]. Age, tumor diameter, 
surgical margin, lymph node status and adjuvant treatment 
had no effect on DFS in multivariate analysis. 
Discussion
Vulvar cancer is a rare tumor with prognostic factors 
described according to retrospective studies [6, 17–19]. 
The main limitation of these studies were heterogeneous 
study groups. The current study showed the experience of 
a tertiary center that had 20-years of experience in gyneco-
logic oncology.  The prognostic factors for OS and DFS were 
investigated in vulvar cancer patients with regular follow-up 
data. Lymph node metastasis had no effect on DFS. OS was 
higher in patients without lymph node metastasis. The dis-
tance to surgical margin lower than 8 mm was found to be 
an independent prognostic factor for OS. 
Vulvar cancer is commonly seen in the elderly popula-
tion. The age of diagnosis was reported to be 68 years [20]. 
Vulvar cancer was reported to occur in younger ages as 
Figure 1. Disease-Free Survival for Lymph Node Status (p = 0.079)
Figure 2. Overall survival for lymph node status (p = 0.028)
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a result of an increase in HPV infection [21, 22]. In accordance 
with these studies, the mean age of the patients at time of 
diagnosis was lower in our study.
Surgery is recommended both for staging and optimal 
treatment in vulvar cancer patients [2].  However, elder pa-
tients with medical comorbidities who cannot undergo sur-
gery or those with advanced disease (in whom it is thought 
that the tumor will not be dissected with negative surgical 
margins) are managed with RT or CRT [2]. The management 
of vulvar cancer should be individualized by multidiscipli-
nary teamwork [3, 4]. Consistent with the recommendations, 
the patients in our study were discussed in a multidisci-
plinary tumor board, and most underwent surgery, while 
patients with advanced disease and medical comorbidities 
were treated with primarily RT or CRT.  The most conserva-
tive individualized treatment was recommended to reduce 
morbidity and increase chance of cure [3]. Modified radical 
vulvectomy was performed in most patients in our study. 
Ipsilateral lymph node dissection was the recommended 
treatment of choice in patients with tumors  < 4 cm in diam-
eter and ≥ 2 cm from midline [4].  Since most of the tumors 
were located at < 2 cm from midline, bilateral lymphadenec-
tomy was performed in most patients in the current study. 
Close surgical margins were reported to be an important 
risk factor for local recurrence [14]. Surgical removal of the 
tumors with negative margins at least 1 cm far from surgi-
Table 3: Factors Effecting Overall and Disease-Free Survival in Vulvar Cancer Patients
Overall survival Disease free survival
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Age 1.06 (1.01–1.11) 0.011 1.07 (1.01–1.12) 0.015 1.04 (0.98–1.09) 0.330 1.0 (0.99–1.11) 0.090
Tumor diameter 1.26 (1.00–1.59) 0.053 1.04 (0.75–1.44) 0.826 1.15 (0.85–1.54) 0.070 1.04 (0.70–1.53) 0.840
Surgical margin
Negative
Positive
Reference
5.30 (2.04 –13.76) 0.001
Reference
4.76 (1.46–15.53) 0.010
Reference 
2.81 (0.59–13.2) 0.020
Reference 
1.80 (0.35–9.20) 0.470
LN metastasis
None 
Yes
Reference
2.31 (1.34–5.11) 0.039 2.54 (0.94–6.86) 0.067
Reference
1.97 (0.75–5.20) 0.460
Reference
1.54 (0.48–4.93) 0.460
Adjuvant treatment
None 
Yes 
Reference
2.14 (0.92–4.99) 0.077
Reference
0.83 (0.23–3.00) 0.772
Reference
2.31 (0.81–6.60) 0.420
Reference
1.84 (0.46–7.25) 0.380
OR —  odds ratio; CI —  confidence interval, Cox regression analyses; LN —  lymph node; Bold p values are < 0.05 and statistically significant
Table 2. Clinicopathological features of patients according to lymph node status 
LN metastasis, n = 23 No LN metastasis, n = 45 
Age, mean ± SD [years], n (%)
< 65
≥ 65
65.7 ± 9.7
13 (56.5)
10 (43.5)
64.2 ± 11.6
21 (53.3)
24 (46.7)
p = 0.60a
p = 0.80c
Tumor diameter, median [range], cm
≤ 4 cm
> 4 cm
3.2 [0.3–6.5]
20 (87.0)
3 (13.0)
2.6 [0.1–8.5)]
40 (88.9)
5 (11.1)
p = 0.01b
p = 1.00f
Tumor localisation, n (%)
Away from midline
Midline
3 (13.0)
20 (87.0)
5 (11.1)
40 (88.9)
p = 1.00f
Grade, n (%)
I
II-III
10 (43.5)
13 (56.5)
24 (53.3)
21 (43.7)
p = 0.44c
LVSI, n (%) 6 (26.1) 3 (6.7) p = 0.05f
Dissected lymph node count, median [range] 10 [8–30] 12 [8–32] p = 0.48b
Positive surgical margin, n (%) 4 (17.4) 2 (5.1) p = 0.43f
Adjuvant treatment, n (%) 22 (95.7) 18 (40.0) p < 0.01c
Recurrence, n (%) 8 (34.8) 10 (22.2) p = 0.27c
a — independent sample t-test; b — Mann-Whitney U-test; c — Chi-Square test; f — Fischer’s exact test; SD — standard deviation; LVSI — lymphovascular space 
invasion; LN — lymph node; bold p values are < 0.05 and statistically significant
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cal margins was recommended. [3]. Since negative surgical 
margin was achieved in most patients, the recurrence rate 
was consistent with the literature. Most women diagnosed 
with vulvar cancer are detected in the early stages of the 
diseases, as we found [6]. 
Local recurrence rate was reported up to 40% in previous 
studies [12]. Heterogeneous study groups in the studies were 
reported to be possible cause of different recurrence rates [14]. 
Maggino et al. [23] reported a recurrence rate of 37% in 
surgically treated vulvar cancer patients. On the other hand, 
a recurrence rate as low as 19% was reported by Sznurkowski 
et al. [6]. Our recurrence rate was consistent with the litera-
ture. This may be due to the difference of the study designs or 
different age groups and adjuvant treatment regimens. Mee-
lapkij et al. [24] examined 145 patients with vulvar SCC and 
detected 5-year survival rate as 50.8%. Although the study 
population was elder in our study, the 5-year survival rate 
was found to be higher. Adjuvant treatment is recommended 
in patients with high-risk for recurrence [3, 4]. However, the 
benefit of adjuvant treatment is not clear for the early stages 
of the disease. In the present study, lymph node positivity, 
margin positivity or tumor diameter greater than 4 cm were 
the criteria for administration of adjuvant treatment as rec-
ommended in NCCN guidelines [4]. Thus, by evaluating the 
patient’s performance status, additional treatments were 
individualized, and the patients were treated with adjuvant 
RT or CRT by obtaining their informed contents.
Because of the rarity of vulvar cancer, the prognostic fac-
tors were evaluated by retrospective studies [6, 25]. Raspa-
glisei et al. [25] reported that the most significant prognostic 
factor was the nodal status. 5-year survival for patients with 
negative nodes ranged from 70% to 93%, and 5-year survival 
for patients with positive nodes ranged from 25% to 41% 
[26]. Similar with the literature, OS for patients with meta-
static nodes were lower in our study.  However, the effect 
of lymph node metastasis on recurrence is conflicting [14]. 
Sznurkowski et al. [9] found that recurrence was more fre-
quent in patients with negative lymph nodes. Conversely, 
Grootenhuis et al. [12] reported that patients with posi-
tive lymph nodes had a higher risk for local recurrence. In 
our study, there was no significant difference between the 
node-positive and node-negative groups in terms of recur-
rence. This result is thought to be related to the fact that 
most of the metastatic patients received adjuvant therapy. 
In addition, it was previously reported that adjuvant radio-
therapy could lead to a lower risk of recurrence, which sup-
ports this idea [14]. Gadduci et al. [13] reported higher local 
recurrence for node-negative patients, but 2-years overall 
survival rate was very low (38%), so the follow-up time was 
shorter for metastatic patients in their study. 
In a prospective study, age was detected as a covariate 
associated with survival, and younger and older patients 
were recommended to be equally treated [27]. In our study, 
age was a significant prognostic factor for OS. Furthermore, 
tumor diameter was not an independent prognostic factor 
for OS [25]. Also, it was reported that tumor diameter had 
no effect on risk of local recurrence [14]. In convenient with 
the literature, tumor diameter had no effect on DFS and OS 
in our study. Most recurrences occur in the surgical field, 
so surgical margin status is an important factor in vulvar 
cancer [2]. The tumor is recommended to be dissected with 
at least 1 cm margin in NCCN and ESGO guidelines [3, 4]. In 
addition, previous studies have been carried out on whether 
close surgical margin increases risk of local recurrence or 
not [14, 15]. In a multicenter European study, 289 surgically 
treated node-negative patients were examined, and margin 
distance had no effect on local recurrence [15]. However, 
a histologic margin of 8 mm or less was detected as a risk 
factor for local recurrence in several studies [9, 28]. In our 
study, positive surgical margin was an important prognostic 
factor for OS, but it was not significant for DFS.
The limitation of our study was its retrospective design. 
However, the number of patients studied was one of the 
highest single-center figures in the literature reported in our 
country. In addition, all patients were cared for in a tertiary 
cancer center with regular follow-up.
CONCLUSIONS
Our results showed that age and surgical margin posi-
tivity were independent prognostic factors for OS.  Lymph 
node metastasis increased the hazard of death; however, it 
was not a predictor for OS. Although surgical margin posi-
tivity increased the risk of recurrence in univariate analysis, 
it was not a significant factor affecting DFS. OS was signifi-
cantly lower in patients with lymph node metastasis.
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